Abstract
Recent advances in our understanding of the diagnosis, imaging, pathology, and clinical monitoring of multiple sclerosis (MS) have significantly increased our ability to successfully treat this often perplexing neurologic disorder. Magnetic resonance imaging (MRI) is now integral to the diagnostic process. Treatment of MS can be considered as three parallel pathways: treatment of relapses, symptom management, and long-term prevention of tissue injury.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
Disease Progression
-
Glatiramer Acetate
-
Glucocorticoids / adverse effects
-
Glucocorticoids / therapeutic use
-
Humans
-
Integrin alpha4
-
Interferon-beta / adverse effects
-
Interferon-beta / therapeutic use
-
Magnetic Resonance Imaging
-
Mitoxantrone / adverse effects
-
Mitoxantrone / therapeutic use
-
Multiple Sclerosis / diagnosis*
-
Multiple Sclerosis / drug therapy*
-
Multiple Sclerosis / pathology
-
Multiple Sclerosis / physiopathology
-
Multiple Sclerosis, Relapsing-Remitting / diagnosis
-
Natalizumab
-
Peptides / adverse effects
-
Peptides / therapeutic use
-
Time Factors
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
Glucocorticoids
-
Natalizumab
-
Peptides
-
Integrin alpha4
-
Glatiramer Acetate
-
Interferon-beta
-
Mitoxantrone